Merus N.V.

Merus N.V. is a clinical-stage oncology company dedicated to discovering and developing innovative, full-length human multispecific antibody therapeutics. Their proprietary technology platforms, known as Multiclonics®, generate a diverse array of antibody binding domains against virtually any target, leading to the creation of novel bispecific and trispecific antibodies. These antibodies are engineered with compelling target combinations to work against the complex mechanisms that drive cancer. Their lead asset, petosemtamab, is a bispecific antibody targeting EGFR and LGR5, showing promising interim clinical results for head and neck cancer.

Merus operates with a global presence, headquartered in Utrecht, The Netherlands, with a US subsidiary in Cambridge, Massachusetts. They are committed to a culture of innovation and collaboration, partnering with leading pharmaceutical and biotechnology companies as well as academic institutions. Their mission is to become a leading oncology product company developing innovative multispecific antibodies to treat various types of cancer, ultimately improving the lives of patients.

Merus offers flexibility in work location, with opportunities to work remotely in addition to their headquarters in Utrecht, The Netherlands and their US subsidiary in Cambridge, MA. While specific job postings may require on-site presence, the company's stated desire to build teams with the most qualified and talented employees suggests openness to remote arrangements for suitable candidates.

Merus prioritizes the well-being of its employees by offering a comprehensive benefits package that includes a competitive salary, a state-of-the-art, social, and flexible workplace, tailored training for individual development, and career opportunities aligned with employee ambitions. This package also includes a highly competitive set of benefits designed to support employee health and well-being.

Merus is a clinical-stage oncology company committed to developing innovative, full-length human multispecific antibody therapeutics, known as Multiclonics®, to address the unmet needs of patients with various types of cancer. Their mission is to "close in on cancer" by discovering and developing leading-edge, targeted treatments that leverage the power of the immune system to fight this devastating disease. Merus strives to create a world where patients have access to effective and innovative therapies that improve their lives.

Merus promotes a culture that is highly purpose-driven, collaborative, and focused on innovation. The company values its employees' individuality and encourages them to share ideas and challenge each other in pursuit of their ambitious mission to close in on cancer. The company's open and human-centric culture fosters a sense of ownership and a commitment to excellence, where employees feel supported and encouraged to grow.

Merus is committed to fostering a diverse, equitable, and inclusive workplace. They pride themselves on equal opportunities for all employees, regardless of race, color, religion, national origin, sex, sexual orientation, age, ancestry, disability, gender identity, military status, or veteran status. Merus values the unique contributions of each individual and enjoys bringing together a variety of perspectives and backgrounds. They are dedicated to this policy across all aspects of employment, from recruitment and hiring to placement, promotion, training, compensation, and benefits.